Independent commentary has been provided by Professor Graeme Jones. Graeme is Professor of Rheumatology and Epidemiology and Head of the Musculoskeletal Unit at the Menzies Research Institute as well as Head of the Department of Rheumatology at Royal Hobart Hospital. He is also the Medical Director of the Arthritis Foundation of Australia.
This review features abatacept (Orencia). Abatacept is a biologic therapy which inhibits the inflammatory cascade at the T cell level by preventing full T cell activation.
Please login below to download this issue (PDF)